These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22773122)

  • 1. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
    Foglietta M; Neelapu SS; Kwak LW; Jiang Y; Nattamai D; Lee ST; Fowler DH; Sportes C; Gress RE; Steinberg SM; Vence LM; Radvanyi L; Dwyer KC; Qazilbash MH; Bryant RN; Bishop MR
    Bone Marrow Transplant; 2013 Feb; 48(2):269-77. PubMed ID: 22773122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
    Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
    Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
    Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
    Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
    Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
    Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
    Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.
    Kwak LW; Taub DD; Duffey PL; Bensinger WI; Bryant EM; Reynolds CW; Longo DL
    Lancet; 1995 Apr; 345(8956):1016-20. PubMed ID: 7723498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
    Tyler EM; Jungbluth AA; Gnjatic S; O'Reilly RJ; Koehne G
    Cancer Immunol Res; 2014 Jun; 2(6):547-58. PubMed ID: 24894092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.
    Franssen LE; Roeven MWH; Hobo W; Doorn R; Oostvogels R; Falkenburg JHF; van de Donk NW; Kester MGD; Fredrix H; Westinga K; Slaper-Cortenbach I; Spierings E; Kersten MJ; Dolstra H; Mutis T; Schaap N; Lokhorst HM
    Bone Marrow Transplant; 2017 Oct; 52(10):1378-1383. PubMed ID: 28581468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
    Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
    Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P; Pan ZK; Paterson Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
    Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW
    Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
    Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.
    Weng J; Cha SC; Matsueda S; Alatrash G; Popescu MS; Yi Q; Molldrem JJ; Wang M; Neelapu SS; Kwak LW
    Clin Cancer Res; 2011 Sep; 17(18):5945-52. PubMed ID: 21813633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
    Neelapu SS; Baskar S; Kwak LW
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
    Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK
    Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.